BACKGROUND: We have shown that continuous systemic delivery of interferon beta (IFN-beta) remodels dysfunctional tumor vasculature, thereby improving tumor perfusion and enhancing delivery and efficacy of chemotherapeutic drugs. We hypothesized that because of their inherent tumor tropism, neural progenitor cells (NPCs) engineered to express IFN-beta could also effect maturation of tumor vasculature without generating high systemic levels of IFN-beta. METHODS: Mice with luciferase-expressing disseminated human neuroblastoma were divided into four groups of equal tumor burden by bioluminescence imaging: (1) untreated controls; (2) NPC-IFN-beta only; (3) cyclophosphamide (CTX) only; and (4) NPC-IFN-beta in combination with CTX. Two million NPC-IFN-beta cells were administered twice, 7 days apart, starting 21 days after tail vein administration of tumor cells. CTX was administered every 6 days for three doses. Mice were killed at 6 weeks, livers and kidneys weighed, and tumor removed for immunohistochemical staining for endothelial cells (CD34), pericytes (alpha-SMA), apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick-end labeling]), and diI-labeled NPCs. RESULTS: Fluorescent-labeled NPCs confirmed localization of these cells to tumors. The alpha-SMA/CD34 ratio, a marker for vascular maturation, greatly increased in NPC-IFN-beta-treated tumors compared with controls. Bioluminescent signal from luciferase-expressing tumor cells, reflecting tumor burden, was lower with combination therapy than control or either monotherapy, and combination therapy resulted in far less tumor burden by weight in the kidneys and liver. CONCLUSIONS: Targeted delivery of IFN-beta with NPCs produced low circulating levels of IFN-beta, yet the maturing effect on the tumor vasculature and the enhanced efficacy of adjuvant therapy was maintained. Thus, combination therapy of NPC-IFN-beta with CTX warrants further investigation for the treatment of high-risk neuroblastoma patients.
BACKGROUND: We have shown that continuous systemic delivery of interferon beta (IFN-beta) remodels dysfunctional tumor vasculature, thereby improving tumor perfusion and enhancing delivery and efficacy of chemotherapeutic drugs. We hypothesized that because of their inherent tumor tropism, neural progenitor cells (NPCs) engineered to express IFN-beta could also effect maturation of tumor vasculature without generating high systemic levels of IFN-beta. METHODS:Mice with luciferase-expressing disseminated humanneuroblastoma were divided into four groups of equal tumor burden by bioluminescence imaging: (1) untreated controls; (2) NPC-IFN-beta only; (3) cyclophosphamide (CTX) only; and (4) NPC-IFN-beta in combination with CTX. Two million NPC-IFN-beta cells were administered twice, 7 days apart, starting 21 days after tail vein administration of tumor cells. CTX was administered every 6 days for three doses. Mice were killed at 6 weeks, livers and kidneys weighed, and tumor removed for immunohistochemical staining for endothelial cells (CD34), pericytes (alpha-SMA), apoptosis (TUNEL [terminal deoxynucleotidyl transferase dUTP nick-end labeling]), and diI-labeled NPCs. RESULTS: Fluorescent-labeled NPCs confirmed localization of these cells to tumors. The alpha-SMA/CD34 ratio, a marker for vascular maturation, greatly increased in NPC-IFN-beta-treated tumors compared with controls. Bioluminescent signal from luciferase-expressing tumor cells, reflecting tumor burden, was lower with combination therapy than control or either monotherapy, and combination therapy resulted in far less tumor burden by weight in the kidneys and liver. CONCLUSIONS: Targeted delivery of IFN-beta with NPCs produced low circulating levels of IFN-beta, yet the maturing effect on the tumor vasculature and the enhanced efficacy of adjuvant therapy was maintained. Thus, combination therapy of NPC-IFN-beta with CTX warrants further investigation for the treatment of high-risk neuroblastomapatients.
Authors: Christian J Streck; Catherine Y C Ng; Youbin Zhang; Junfang Zhou; Amit C Nathwani; Andrew M Davidoff Journal: Cancer Lett Date: 2005-10-18 Impact factor: 8.679
Authors: John M Kirkwood; Thomas Richards; Hassane M Zarour; Jeffrey Sosman; Marc Ernstoff; Theresa L Whiteside; Joseph Ibrahim; Ronald Blum; Samuel Wieand; Ruth Mascari Journal: Cancer Date: 2002-09-01 Impact factor: 6.860
Authors: Alice B Brown; Wendy Yang; Nils O Schmidt; Rona Carroll; Kim K Leishear; Nikolai G Rainov; Peter M Black; Xandra O Breakefield; Karen S Aboody Journal: Hum Gene Ther Date: 2003-12-10 Impact factor: 5.695
Authors: Christian J Streck; Youbin Zhang; Ryan Miyamoto; Junfang Zhou; Catherine Y c Ng; Amit C Nathwani; Andrew M Davidoff Journal: Surgery Date: 2004-08 Impact factor: 3.982
Authors: Ricky T Tong; Yves Boucher; Sergey V Kozin; Frank Winkler; Daniel J Hicklin; Rakesh K Jain Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701
Authors: Margarita Gutova; Joseph A Frank; Massimo D'Apuzzo; Vazgen Khankaldyyan; Megan M Gilchrist; Alexander J Annala; Marianne Z Metz; Yelena Abramyants; Kelsey A Herrmann; Lucy Y Ghoda; Joseph Najbauer; Christine E Brown; M Suzette Blanchard; Maciej S Lesniak; Seung U Kim; Michael E Barish; Karen S Aboody; Rex A Moats Journal: Stem Cells Transl Med Date: 2013-09-06 Impact factor: 6.940
Authors: C Marin-Bañasco; K Benabdellah; C Melero-Jerez; B Oliver; M J Pinto-Medel; I Hurtado-Guerrero; F de Castro; D Clemente; O Fernández; F Martin; L Leyva; M Suardíaz Journal: Br J Pharmacol Date: 2017-01-12 Impact factor: 8.739